Cardiogen
Ala-Glu-Asp-Arg · AEDR · Cardiac bioregulator
Think of it as a maintenance crew for your heart's genetic blueprint.
Cardiogen is like a tiny team of genetic whisperers, focusing on your heart. It's designed to slip into heart cells and tweak the way certain genes express themselves. Imagine it as a coach giving pep talks to your heart cells, encouraging them to stay strong and function well, even as time marches on.
The research behind Cardiogen suggests it might help maintain heart health as you age, potentially keeping your heart tissue and blood vessels in better shape. Most of the insights come from lab studies and some preclinical work, so it's still in the exploratory phase. It's not FDA-approved, meaning it's not yet recognized as a standard treatment. However, it's an intriguing area of study for those curious about longevity and heart health.
Who it's for
- Biohackers interested in exploring cutting-edge heart health strategies
- Middle-aged individuals curious about maintaining heart vitality
- Science enthusiasts following peptide research
Probably not for you if…
- Those expecting a quick-fix solution for heart issues
- Individuals seeking FDA-approved treatments
- People uncomfortable with experimental research findings
Editorial summary for research context · Not medical advice
Mechanism of Action
Cardiogen is a short synthetic tetrapeptide (Ala-Glu-Asp-Arg) designed as a cardiac-tissue bioregulator. Khavinson-group research proposes that short peptides penetrate the cell membrane, enter the nucleus, bind DNA promoter regions, and modulate tissue-specific gene expression — in this case in cardiomyocytes and coronary vasculature. Not FDA-approved. Preclinical and limited human data from Khavinson group.
Researched Benefits
Cardiomyocyte gene expression modulation
Khavinson-lab cell-culture work reports modulation of gene expression in cardiac tissue preparations with proposed relevance to age-related decline.
- [Khavinson et al. 2011]
Preclinical cardiac aging research
Russian-language preclinical studies have examined effects on cardiac morphology and functional markers in aged rodent models.
- [Kuznik et al. 2014]
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Intranasal research protocol
- Dosage
- 100 mcg
- Frequency
- once daily
- Timing
- morning
- Cycle
- 3 weeks
Khavinson-group protocols have typically used 20-30 day cycles, often repeated 2x per year.
Reported Side Effects
- No serious adverse events reported in published Khavinson-group studies
- Transient local irritation with intranasal delivery
- Long-term human safety data limited
Contraindications
- Pregnancy and lactation (no safety data)
- Active cardiac malignancy or myxoma (theoretical concern)
- Individual hypersensitivity to peptide components
Stacking Partners
Peptides commonly paired with Cardiogen in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
7:14What Science ACTUALLY Says About BPC 157 Benefits
Jeffrey Peng MD
545K views · 7:14 · 2 years ago
6:04Doctor Explains 20 Most Powerful Peptides
This Is Not Covered - Dr. Ashley Froese
472.6K views · 6:04 · 7 months ago
8:07Boost Cardio By 75% || Breakthrough Research On Cardarine Gw501516
Greg Doucette
248.3K views · 8:07 · 3 years ago
19:35Cardiogenic Shock | Shock (Part 4)
ICU Advantage
185.2K views · 19:35 · 6 years ago
18:21Top 10 Peptides For 2026
Dr. Jones, DC
87.6K views · 18:21 · 4 months ago
Research Papers
Short peptides regulate gene expression, protein synthesis, and cell functions
Khavinson VKh, Linkova NS, Tarnovskaya SI · Bulletin of Experimental Biology and Medicine · 2016
Peptidergic regulation of cardiac functions in aging
Kuznik BI, et al. · Advances in Gerontology · 2014